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1. Introduction
There are underlying concerns regarding the safety of vitrectomy surgery in eyes with intra‐
ocular malignancy. These concerns are associated with vitrectomy, both with or without pla‐
que brachytherapy for choroidal melanoma. These include the possibility of local tumor
dissemination, extension of malignant cells to the ocular surface and orbit, and remote meta‐
stasis. The purpose of this chapter is to discuss the safety and efficacy of employing pars
plana vitrectomy in the setting of choroidal melanoma, whether concurrent with treatment
or post radiation treatment.
Uveal melanomas are the most common primary intraocular malignancy and, besides the
skin, the uvea is the area most commonly affected by melanoma. The incidence of ocular
melanoma in the United States is approximately six cases per one million population each
year with a median age of onset of 55 years. [1,2] Distant metastasis peaks two to three years
after enucleation with uveal melanomas, and patients with remote metastasis seldom sur‐
vive longer than one year. [3]
Currently, treatments for remote metastasis include immunotherapy, hepatic chemoemboli‐
zation, as well as experimental treatment modalities. Unfortunately, survival has not dra‐
matically increased with any of the current treatment modalities for metastatic choroidal
melanoma. Many factors have been suggested as being of prognostic value including larger
tumor size, anterior tumor margin, cellular pleomorphism, extrascleral extension, and genet‐
ics including monosomy 3 and genetic expression profiling. These will be discussed in later
paragraphs.
The indications for pars plana vitrectomy (PPV) have increased exponentially since its in‐
ception in the 1970s. Traditionally, 20-gauge PPV has caused delayed wound healing, re‐
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quirement of sclerotomy sutures, postoperative astigmatism, and patient discomfort.
Recently, small gauge PPV has been introduced. The 25-gauge transconjunctival sutureless
PPV system enables sutureless three-port PPV without the need for conjunctival peritomies,
decreases mean operative times, reduces post surgical patient discomfort, and decreases sur‐
gically-induced trauma at sclerotomy sites. [4] Decreased traumatic conjunctival and scleral
manipulation with less postop inflammation, as well as less induced astigmatism, allows for
more rapid postoperative visual recovery. The self-sealing nature of the incisions in suture‐
less PPV, however, does pose potential concerns for the possibility of vitreous incarceration,
postoperative endophthalmitis, and hypotony. [5-7]
Posterior uveal melanomas can cause visual disturbances secondary to vitreous hemor‐
rhage, exudative retinal detachments, and radiation-related complications. Treatment con‐
sisted of enucleation prior to the Collaborative Ocular Melanoma Study (COMS), which
found that at twelve years, there were no significant differences in survival between enu‐
cleation and plaque brachytherapy with regards to medium size choroidal melanomas. [8]
Radiation has resulted in a new set of complications, some of which are amenable to the use
of vitrectomy surgery in the setting of a treated choroidal melanoma. This chapter will dis‐
cuss the safety and efficacy of vitrectomy regarding diagnosis and biopsy, endoresection,
and radiation-induced complications.
2. Pars plana vitrectomy for diagnostic biopsy as well as molecular
genetic testing
The diagnosis of posterior choroidal melanoma is often made clinically, as well as aided by
ancillary testing, such as ultrasonography, optical coherence tomography, transillumination,
and angiography. Choroidal melanoma rarely requires a biopsy to make the diagnosis. With
the advent of cytogenetic and molecular genetic studies, there has been a recent effort to ob‐
tain fresh tumor tissue. Early cytogenetic studies suggested that certain chromosomes (chro‐
mosome 3, 6, and 8) abnormalities were associated with a higher likelihood for metastatic
disease. In the early 1990s, it was recognized that a chromosomal 3 alteration was closely
associated with metastatic disease. The most important was monosomy 3 (loss of one copy
of chromosome 3), which is closely associated with metastatic disease. [9,10]
Other chromosomal changes have been associated with metastatic disease including loss of
1p and 8p as well as gain of 8q, loss of 6q, and gain of 6p. These have been linked statistical‐
ly to metastatic death in choroidal melanoma. [11]
This cytogenetic information has become increasingly accessible to physicians, and the risk
of misinterpreting this information has also increased. Cytogenetic analysis for choroidal
melanoma was first performed with standard karyotyping, in which direct visualization
was used and chromosomal abnormalities identified by morphologic changes and chromo‐
some banding pattern and size. However, this technique required the need for a highly
trained cytogeneticist, led to sampling error due to analysis of only a few tumor cells, and
had an inability to detect small changes. There are other techniques that rely on direct analy‐
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sis of chromosomes including spectral karyotyping (SKY), fluorescence in situ hybridization
(FISH), and comparative genomic hybridization (CGH).
The above techniques were superior to clinical and histopathologic variables alone in pre‐
dicting which patients will develop metastatic disease. However, these techniques had limi‐
tations including false positives and negatives, a high rate of failure due to the amount of
tissue required, the variability of technique from center to center, and intratumoral hetero‐
geneity. Perhaps the most limiting factor in the accuracy of monosomy 3 analysis is due to
heterogeneity. A single choroidal melanoma can be comprised of a mixture of cells, some of
which contain one copy of chromosome 3 and others that contain the normal two copies.
Sampling one portion of the tumor can often produce the wrong test result.
Recently, thousands of genes could be monitored simultaneously for micro-RNA (mRNA)
expression. [12] With the advent of newer software, massive amounts of data could be ana‐
lyzed and multidimensional analysis could provide new heights of biologic information that
were previously unobtainable. This was seen in cancer, where gene expression profiling
(GEP) revealed many types of cancer that were thought to be uniform based on their com‐
mon tissue source, but were instead composed of multiple subtypes of molecularly distinct
cancers. This was the case with choroidal melanoma. GEP has helped to simplify our molec‐
ular understanding of choroidal melanoma. Rather than many different molecular subtypes,
there are only two major choroidal melanoma subtypes, class 1 and class 2. GEP is extremely
accurate for predicting patient metastatic rates. Class 1 tumors have a very low risk and
class 2 have a very high risk of metastatic disease. [12]
The superiority of GEP over monosomy 3 has been verified by multiple groups. [12] In the
past, the major disadvantage of GEP was the expense and limited availability. [13] However,
once the value of GEP became clear, considerable effort was devoted to optimizing it for ap‐
plication and use. With regards to choroidal melanoma, GEP evaluates 15 different genetic
abnormalities resulting in a class 1 or class 2 classification. This small number of genes has
allowed a commercially available, relatively inexpensive assay. This is a polymerase chain
reaction based assay, which requires a much smaller biopsy sample and has a very low fail‐
ure rate. With this technology, we can now identify uveal melanoma patients who are likely
to develop metastatic disease. But the question remains, what is the role of vitrectomy with
regards to biopsying choroidal melanoma?
Obtaining cells for analysis requires a fine-needle aspiration biopsy (FNAB). Techniques for
performing biopsy may be transvitreal or transscleral. Newer techniques even involve the
use of small gauge vitrectomy. Transscleral biopsy involves the use of a 27- or 30-gauge nee‐
dle that is inserted tangentially through the sclera at the base of the tumor. Traditionally fol‐
lowing transscleral biopsy, a radioactive plaque is then placed. Transvitreal biopsy may also
be performed with a 25- or 27-gauge needle via a pars plana approach. The needle is insert‐
ed into the tumor and tumor cells are aspirated. [14] Paul Finger, M.D. was a pioneer in in‐
troducing the 25-gauge vitrector to biopsy ocular melanomas. He first used the technique to
aspirate cells from an iris melanoma. [13] More recently with the advent of sutureless vitrec‐
tomy, newer techniques include performing a 25-gauge vitrectomy followed by inserting a
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25- or 27-gauge needle through the 25-gauge cannula and into the center of the tumor, fol‐
lowed by aspiration of tumor cells. [15]
Potential complications of biopsy include vitreous hemorrhage, retinal detachment, and the
potential for intraocular or extraocular tumor dissemination. In a series of 500 fine needle
biopsy procedures, there were no cases of local recurrence or intraocular dissemination. [16]
However, follow up was only three years. There were no cases of extrascleral extension due
to FNAB. In another publication by Shields et al, they focused on the outcome of each pa‐
tient after FNAB. [17] Each patient was treated with plaque brachytherapy at the time of
FNAB, and there were no enucleations as all biopsy specimens were obtained by needle
sampling. There were no complications in this study as well. Twenty-five-gauge PPV using
the vitrector to obtain cells has also resulted in no intraocular dissemination or increased
metastasis to date. [13,15]
Most recently, investigators at the Jules Stein Eye Institute performed an Institutional Re‐
view Board approved retrospective study to evaluate local and systemic outcomes in pa‐
tients undergoing FNAB at the time of plaque surgery for choroidal melanoma. Included
were all patients with choroidal melanoma treated with Iodine-125 brachytherapy and intra‐
operative transscleral FNAB from 2005 to 2010. [18] The study included 170 consecutive pa‐
tients. The technique used for FNAB involved transscleral approach using a 30-gauge
needle. They found no cases of treatment failure and there were no cases of orbital dissemi‐
nation. Metastatic disease developed in 14 of the 170 patients. The metastatic rate in their
study was similar to the metastatic rate in the COMS. The COMS did not include FNAB of
tumors. In this study, when compared with the largest multicenter prospective study ever
performed in ocular oncology, performing FNAB did not increase the risk of developing
metastatic disease from choroidal melanoma.
3. Pars plana vitrectomy for treatment of choroidal melanoma using
endoresection
Removal of a tumor using an internal approach (endoresection) was first investigated for
posterior choroidal melanomas in the 1980s, primarily for small juxtapapillary melanomas
that were not amenable to other forms of treatment including brachytherapy at that time.
Endoresection has never gained widespread popularity. However, studies have investigated
the use of endoresection as an alternative to plaque brachytherapy to avoid radiation related
complications such as radiation retinopathy, optic neuropathy, and retinal ischemia. Surgi‐
cal techniques vary dependent upon surgeon, however the basic principles remain. A three-
port PPV is performed with posterior hyaloid dissection. Diathermy or endolaser is used
around the periphery of the tumor, followed by creation of a retinotomy. The vitreous cutter
is used to excise the tumor to bare sclera. Photocoagulation is then used followed by gas or
silicone oil tamponade to flatten the retina. This surgical technique has many complications
including retinal detachment, proliferative vitreoretinopathy, severe bleeding, and cataract.
The results for local tumor control and metastasis have been favorable, with complications
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ranging from 2% to 9.4%. [19-22] A very large risk and potential drawback has been the
question of whether this procedure results in liberating active tumor causing a potential in‐
crease in orbital recurrence and metastatic disease. This question will be answered by the
studies cited below.
Kertes et al,  in the British Journal of  Ophthalmology,  followed 32 consecutive patients that
were  treated  with  endoresection.  The  patient’s  choroidal  melanoma  was  pathologically
confirmed and all patients were followed for a mean of 40.1 months. At the time, this was
the  longest  follow up  and  largest  series  reporting  on  endoresection  for  posterior  uveal
melanoma. [19] The authors found that only three patients developed distant metastasis
and died of malignant melanoma. In one case, distant metastasis developed in association
with an intraocular recurrence. The most common complications the authors encountered
were vitreous hemorrhage in 37.5% of patients, cataract in eight of 32 eyes, and three cas‐
es of retinal detachment. With an average of almost three and one-half years follow up,
the authors concluded that their results, with regards to metastatic disease, were no worse
than patients treated with plaque brachytherapy. They stated that their experience did not
support the contention that surgical manipulation of malignant choroidal melanoma pro‐
motes metastasis.  Furthermore,  endoresection is  a  reasonable and safe alternative to the
management of posterior uveal melanoma. Approximately 50% of uveal melanomas occur
less than 3mm from the optic nerve or fovea, and the authors felt that their technique was
particularly well suited to the treatment of choroidal melanomas that are in close proximi‐
ty to the optic nerve and fovea.
Damato and associates, in a 1998 British Journal of Ophthalmology article, reported on 52 pa‐
tients undergoing endoresection for choridal melanoma. Their technique involved vitrecto‐
my, retinal incision, hemostasis by raising intraocular pressure and by moderate
hypotensive anesthesia, endoresection using the vitrector, endodiathermy, endolaser, and
fluid-air exchange to reattach the retina. [20] They used adjunctive ruthenium plaque radio‐
therapy in selected cases. Their patients had a mean tumor thickness of 3.9 mm. Most of the
choroidal melanomas extended to within two disc diameters of the optic nerve. Follow up
was a median of 20 months. The main complications included retinal detachment in 16 of 52
patients and cataract in 25 of 52 patients. Twenty-three of the 52 patients had 20/200 or bet‐
ter vision postoperatively. No patients developed local tumor recurrence. Only one of the 52
patients undergoing endoresection developed metastatic disease, 41 months postoperative‐
ly. The authors concluded that endoresection did not increase the rate of metastatic disease.
Garcia-Arumi and associates reported on 25 consecutive patients undergoing vitreoretinal
surgery with endoresection for high posterior choroidal melanomas. [21] The tumor thick‐
ness ranged from 9.1 mm to 12.8 mm. The authors employed standard endoresection techni‐
que, but did use a 120-degree anterior retinotomy prior to endoresecting the melanoma and
reattaching the retina. The postoperative complications included cataract in 40%, retinal de‐
tachment in 16%, epiretinal macular proliferation in 8%, and submacular hemorrhage in 4%.
The final visual acuity postoperatively ranged from hand motion to 20/30, with a mean of
20/100. Remarkably, no tumors recurred, and there was no evidence of metastatic disease in
follow up, which ranged from 12 to 72 months. The authors state that the reason for having
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such a low rate of retinal detachment was due to modifying their technique, including trim‐
ming the vitreous base, examining the peripheral retina carefully for breaks, and avoiding
high infusion pressure. These authors also concluded that endoresection was efficacious and
did not increase the rate of metastatic disease.
Most recently, Karkhaneh and associates reported on 20 patients undergoing endoresection
for medium size posterior choroidal melanoma. [22] Tumor thickness ranged from 5.5 mm
to 11 mm. Preoperative visual acuity ranged from hand motion to 20/40, while postoperative
visual acuity ranged from no light perception to 20/30. The authors stated that for tumors
with thickness less than 9 mm in their study, they could have been treated with radiothera‐
py, but endoresection of the tumor may be an alternative approach in some parts of the
world where radiotherapy is not readily available. Of the authors’ patients, 6.7% had 20/40
or better vision at three years, while 73% had 20/200 or less. Only one in 20 patients died of
metastatic disease in a mean follow up of 89.5 months. This is the longest follow up of all
case series of patients undergoing endoresection for choroidal melanoma. This rate of meta‐
static disease is certainly lower than the metastatic rate seen in the COMS.
In contrast to enucleation, endoresection of posterior choroidal melanoma is designed to
preserve vision and maintain a cosmetically acceptable eye. In contrast to brachytherapy,
endoresection has fewer long-term complications such as radiation optic neuropathy or ra‐
diation retinopathy. Immediate complications of endoresection can be severe, including vit‐
reous hemorrhage, retinal detachment, cataract, and proliferative vitreoretinopathy. [19-22]
The primary goal of endoresection is to eradicate the tumor while preserving vision. How‐
ever, the question of cutting into a malignant tumor and liberating cells, some of which may
lead to local tumor recurrence or orbital tumor recurrence and/or distant metastasis, needed
to be answered. There is no current evidence that endoresection of posterior choroidal mela‐
noma is different from enucleation or brachytherapy with regard to patient survival and
metastatic disease, seen in the above detailed literature. [19-22]
4. Pars plana vitrectomy for exudative retinal detachment secondary to
choroidal melanoma
Exudative retinal detachment is the most common etiology of vision loss from untreated,
recently diagnosed choroidal melanoma. Historically, management has been conservative,
as the exudative retinal detachment will often resolve following brachytherapy for choroi‐
dal melanoma. However, large exudative retinal detachments secondary to choroidal mel‐
anoma often will not resolve and can lead to irreversible vision loss from photoreceptor
damage during the several months needed for post brachytherapy resolution. The consis‐
tency of subretinal fluid associated with exudative retinal detachment from choroidal mel‐
anoma  is  found  to  be  more  viscous  compared  to  subretinal  fluid  in  rhegmatogenous
retinal detachments, which can explain the longer duration of reabsorption leading to lim‐
ited visual recovery. [23]
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Gibran  and Kapoor  reported  on  six  consecutive  patients  with  choroidal  melanoma and
secondary exudative retinal detachment that underwent radiation therapy, transretinal bi‐
opsy with the 25-gauge vitrector, and surgical treatment of the exudative retinal detach‐
ment, including vitrectomy and drainage of subretinal fluid with retinal tamponade. [23]
All patients had a successful reattachment of the retina with significant restoration of vi‐
sion. There were no recurrences of exudative retinal detachment. Five of the six patients
had 20/40 or better vision postoperatively. More importantly, there were no cases of extra‐
scleral extension or metastatic disease.
5. Pars plana vitrectomy for complications after brachytherapy for
choroidal melanoma
Posterior choroidal melanoma treated by brachytherapy can often result in decreased visual
acuity due to retinal detachment, vitreous hemorrhage, radiation retinopathy, radiation op‐
tic neuropathy, radiation macular ischemia, epimacular proliferation, vitreous debris, and
cataract. Potential indications for vitrectomy following melanoma brachytherapy include
exudative retinal detachment, tractional and rhegmatogenous retinal detachment, vitreous
hemorrhage, vitreous debris, and epimacular proliferation.
There is controversy regarding surgical treatment of eyes harboring a melanoma, whether
treated or untreated, and whether there are viable tumor cells that may increase intraocular
recurrence, extraocular recurrence, and metastatic disease. This question will be answered
by the articles discussed below, as well as our data at Retina Consultants of Alabama/The
University of Alabama at Birmingham School of Medicine, Department of Ophthalmology.
Foster and associates reported on nine patients undergoing 20-gauge PPV in eyes contain‐
ing a treated posterior uveal melanoma. [24] In their series, vitrectomy was performed for
vitreous hemorrhage in five patients, macular pucker in two patients, macular hole in one
patient,  and  rhegmatogenous  retinal  detachment  in  one  patient.  Vitrectomy  was  per‐
formed at a mean 24.7 months after melanoma radiation treatment. Dispersion of tumor
cells during vitrectomy was not observed in any patient. One patient had melanoma cells
detected in the vitreous aspirate. This patient had intratumoral and vitreous hemorrhage
before  plaque  brachytherapy,  underwent  combined  cataract  extraction  and  vitrectomy,
and developed intraocular tumor dissemination 56 months after vitrectomy. No other pa‐
tients  developed intraocular  tumor  dissemination.  None  of  the  nine  patients  developed
systemic metastatic disease.
More recently, Bansal et al reported on the author’s experience with vitrectomy for vitreous
hemorrhage in eyes with posterior choroidal melanoma. [25] They reviewed the medical re‐
cords of 47 patients who underwent vitrectomy for vitreous hemorrhage following Io‐
dine-125 brachytherapy for posterior choroidal melanoma. The primary outcome of their
analysis included rates of intraocular tumor dissemination, extrascleral extension, local tu‐
mor recurrence, and systemic metastasis. The average time to develop vitreous hemorrhage
was 22 months following brachytherapy. With a mean follow up of five years, only four of
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the 47 patients (8%) developed metastatic disease, and no cases had intraocular tumor dis‐
semination or extraocular extension.
In 2012, Sisk and Murray reported on combined phacoemulsification and sutureless vitrec‐
tomy for complex vitreoretinal diseases. [26] In their retrospective review of 114 eyes that
had vitrectomy and cataract extraction, 72 of these eyes had a diagnosis of melanoma post
radiation treatment. The authors’ primary outcome measures were visual acuity and perio‐
perative complications. They did not report on tumor recurrence or metastatic disease.
We at Retina Consultants of Alabama/The University of Alabama at Birmingham School of
Medicine, Department of Ophthalmology reviewed the medical records of 155 consecutive
patients with choroidal melanoma treated with Iodine-125 brachytherapy. [15] We identified
20 patients that subsequently underwent 25-gauge PPV following brachytherapy. The aver‐
age age was 64. The etiology for 25-gauge PPV was epimacular proliferation in one patient,
vitreous debris in two patients, rhegmatogenous retinal detachment in three patients, exu‐
dative retinal detachment in one patient, and vitreous hemorrhage in 13 patients. The aver‐
age interval from plaque brachytherapy to 25-gauge vitrectomy was 59 months (range 16 to
98 months). Patients were followed after their 25-gauge PPV an average of 36 months (range
nine to 100 months). We found one of 20 patients to have local intraocular recurrence. One
patient subsequently was enucleated for a blind painful eye secondary to neovascular glau‐
coma. Sixteen of the 20 patients had improvement in vision following PPV. Most important‐
ly, no systemic metastatic disease was reported in any of the 20 patients at their last visit,
which was a mean of 36 months following their 25-gauge PPV.
In summary, the reports by Foster et al, [24] Bansal et al, [25] and Mason and Mullins [15]
reveal the safety of performing vitrectomy in patients who have been treated with brachy‐
therapy for choroidal melanoma. The combined reports by Foster and Mason found zero of
29 patients developed metastatic disease following vitrectomy, while Bansal found only four
of 47 patients to have developed metastatic disease following vitrectomy in patients with
treated choroidal melanoma. This meta-analysis certainly reveals a much lower incidence of
metastatic disease than previous reports, including the COMS (which did not include PPV
following brachytherapy). [8] Our current findings based on the above literature, are the fol‐
lowing: sutureless vitrectomy may be performed safely in patients having post brachythera‐
py complications, sutureless vitrectomy does not increase the rate of metastatic disease, and,
patients may take comfort that vitrectomy following brachytherapy for choroidal melanoma
may result in an increase in vision with no threat of increasing metastatic disease.
6. Conclusion
With the advent of globe salvaging techniques regarding management of choroidal mela‐
noma,  ocular  oncologists  face  challenges  in  the  care  of  these  patients.  Tumor  biopsy  is
gaining  widespread  acceptance  to  obtain  tissue  for  genetic  analyses,  allowing  for  more
precise determination of metastatic disease prognosis. The use of vitrectomy with regards
to tumor biopsy,  endoresection,  and post  radiation complications has expanded rapidly.
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Fortunately, all literature to date has shown PPV to be very efficacious and safe in the set‐
ting of a patient with choroidal melanoma. Furthermore, there has been no increased rate
of metastasis of choroidal melanoma when vitrectomy has been employed prior to or fol‐
lowing treatment of the tumor.
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